Skip to main content
Top

Open Access 20-04-2024 | Human Immunodeficiency Virus | Original Research

Underlying Neural Mechanisms of Cognitive Improvement in Fronto-striatal Response Inhibition in People Living with HIV Switching Off Efavirenz: A Randomized Controlled BOLD fMRI Trial

Authors: Patrick G. A. Oomen, Charlotte S. Hakkers, Joop E. Arends, Guido E. L. van der Berk, Pascal Pas, Andy I. M. Hoepelman, Berend J. van Welzen, Stefan du Plessis

Published in: Infectious Diseases and Therapy

Login to get access

Abstract

Introduction

It is unclear whether neurotoxicity due to the antiretroviral drug efavirenz (EFV) results in neurocognitive impairment in people living with HIV (PLWH). Previously, we found that discontinuing EFV was associated with improved processing speed and attention on neuropsychological assessment. In this imaging study, we investigate potential neural mechanisms underlying this cognitive improvement using a BOLD fMRI task assessing cortical and subcortical functioning.

Methods

Asymptomatic adult PLWH stable on emtricitabine/tenofovirdisoproxil/efavirenz were randomly (1:2) assigned to continue their regimen (n = 12) or to switch to emtricitabine/tenofovirdisoproxil/rilpivirine (n = 28). At baseline and after 12 weeks, both groups performed the Stop-Signal Anticipation Task, which tests reactive and proactive inhibition (indicative of subcortical and cortical functioning, respectively), involving executive functioning, working memory, and attention. Behavior and BOLD fMRI activation levels related to processing speed and attention Z-scores were assessed in 17 pre-defined brain regions.

Results

Both groups had comparable patient and clinical characteristics. Reactive inhibition behavioral responses improved for both groups on week 12, with other responses unchanged. Between-group activation did not differ significantly. For reactive inhibition, positive Pearson coefficients were observed for the change in BOLD fMRI activation levels and change in processing speed and attention Z-scores in all 17 regions in participants switched to emtricitabine/tenofovir disoproxil/rilpivirine, whereas in the control group, negative correlation coefficients were observed in 10/17 and 13/17 regions, respectively. No differential pattern was observed for proactive inhibition.

Conclusion

Potential neural mechanisms underlying cognitive improvement after discontinuing EFV in PLWH were found in subcortical functioning, with our findings suggesting that EFV’s effect on attention and processing speed is, at least partially, mediated by reactive inhibition.

Trial Registration

Clinicaltrials.gov identifier [NCT02308332].
Appendix
Available only for authorised users
Literature
1.
go back to reference Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853–60.CrossRefPubMed Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853–60.CrossRefPubMed
2.
go back to reference Pourcher V, Gourmelen J, Bureau I, Bouee S. Comorbidities in people living with HIV: an epidemiologic and economic analysis using a claims database in France. PLoS ONE. 2020;15:1–15.CrossRef Pourcher V, Gourmelen J, Bureau I, Bouee S. Comorbidities in people living with HIV: an epidemiologic and economic analysis using a claims database in France. PLoS ONE. 2020;15:1–15.CrossRef
3.
go back to reference Antinori A, Arendt G, Becker JT, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology. 2007;69:1789–99.CrossRefPubMed Antinori A, Arendt G, Becker JT, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology. 2007;69:1789–99.CrossRefPubMed
4.
go back to reference Tozzi V, Costa M, Sampaolesi A, et al. Neurocognitive performance and quality of life in patients with HIV infection. AIDS Res Hum Retrovir. 2003;19:643–52.CrossRefPubMed Tozzi V, Costa M, Sampaolesi A, et al. Neurocognitive performance and quality of life in patients with HIV infection. AIDS Res Hum Retrovir. 2003;19:643–52.CrossRefPubMed
6.
go back to reference Underwood J, Robertson KR, Winston A. Could antiretroviral neurotoxicity play a role in the pathogenesis of cognitive impairment in treated HIV disease? AIDS. 2014;29:253–61.CrossRef Underwood J, Robertson KR, Winston A. Could antiretroviral neurotoxicity play a role in the pathogenesis of cognitive impairment in treated HIV disease? AIDS. 2014;29:253–61.CrossRef
7.
go back to reference Heaton RK, Franklin DR, Ellis RJ, et al. HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol. 2011;17:3–16.CrossRefPubMed Heaton RK, Franklin DR, Ellis RJ, et al. HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol. 2011;17:3–16.CrossRefPubMed
8.
go back to reference Decloedt EH, Maartens G. Neuronal toxicity of efavirenz: a systematic review. Expert Opin Drug Saf. 2013;12:841–6.CrossRefPubMed Decloedt EH, Maartens G. Neuronal toxicity of efavirenz: a systematic review. Expert Opin Drug Saf. 2013;12:841–6.CrossRefPubMed
9.
go back to reference World Health Organization. Updated recommendations on HIV prevention, infant diagnosis, antiretroviral initiation and monitoring. Geneva: WHO; 2021. World Health Organization. Updated recommendations on HIV prevention, infant diagnosis, antiretroviral initiation and monitoring. Geneva: WHO; 2021.
10.
go back to reference Gupta A, Juneja S, Vitoria M, et al. Projected uptake of new antiretroviral (ARV) medicines in adults in low- and middle-income countries: a forecast analysis 2015–2025. PLoS ONE. 2016;11:1–18.CrossRef Gupta A, Juneja S, Vitoria M, et al. Projected uptake of new antiretroviral (ARV) medicines in adults in low- and middle-income countries: a forecast analysis 2015–2025. PLoS ONE. 2016;11:1–18.CrossRef
11.
go back to reference Ciccarelli N, Fabbiani M, Di Giambenedetto S, et al. Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients. Neurology. 2011;76:1403–9.CrossRefPubMed Ciccarelli N, Fabbiani M, Di Giambenedetto S, et al. Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients. Neurology. 2011;76:1403–9.CrossRefPubMed
12.
go back to reference Asundi A, Robles Y, Starr T, et al. Immunological and neurometabolite changes associated with switch from efavirenz to an integrase inhibitor. JAIDS J Acquir Immun Defic Syndr. 2019;81:585–93.CrossRef Asundi A, Robles Y, Starr T, et al. Immunological and neurometabolite changes associated with switch from efavirenz to an integrase inhibitor. JAIDS J Acquir Immun Defic Syndr. 2019;81:585–93.CrossRef
13.
go back to reference Robertson KR, Su Z, Margolis DM, et al. Neurocognitive effects of treatment interruption in stable HIV-positive patients in an observational cohort. Neurology. 2010;74:1260–6.CrossRefPubMedPubMedCentral Robertson KR, Su Z, Margolis DM, et al. Neurocognitive effects of treatment interruption in stable HIV-positive patients in an observational cohort. Neurology. 2010;74:1260–6.CrossRefPubMedPubMedCentral
14.
go back to reference Ma Q, Vaida F, Wong J, et al. Long-term efavirenz use is associated with worse neurocognitive functioning in HIV-infected patients. J Neurovirol. 2016;22:170–8.CrossRefPubMed Ma Q, Vaida F, Wong J, et al. Long-term efavirenz use is associated with worse neurocognitive functioning in HIV-infected patients. J Neurovirol. 2016;22:170–8.CrossRefPubMed
15.
16.
go back to reference Nwogu JN, Gandhi M, Owen A, et al. Associations between efavirenz concentrations, pharmacogenetics and neurocognitive performance in people living with HIV in Nigeria. AIDS. 2021;35:1919–27.CrossRefPubMed Nwogu JN, Gandhi M, Owen A, et al. Associations between efavirenz concentrations, pharmacogenetics and neurocognitive performance in people living with HIV in Nigeria. AIDS. 2021;35:1919–27.CrossRefPubMed
17.
go back to reference Tiraboschi J, Hamzah L, Teague A, et al. Short communication: the impact of switching from atripla to darunavir/ritonavir monotherapy on neurocognition, quality of life, and sleep: results from a randomized controlled study. AIDS Res Hum Retrovir. 2016;32:1198–201.CrossRefPubMed Tiraboschi J, Hamzah L, Teague A, et al. Short communication: the impact of switching from atripla to darunavir/ritonavir monotherapy on neurocognition, quality of life, and sleep: results from a randomized controlled study. AIDS Res Hum Retrovir. 2016;32:1198–201.CrossRefPubMed
18.
go back to reference Hakkers CS, Arends JE, Van Den Berk GE, et al. Objective and subjective improvement of cognition after discontinuing efavirenz in asymptomatic patients: a randomized controlled trial. J Acquir Immune Defic Syndr. 1988;2019(80):E14–22. Hakkers CS, Arends JE, Van Den Berk GE, et al. Objective and subjective improvement of cognition after discontinuing efavirenz in asymptomatic patients: a randomized controlled trial. J Acquir Immune Defic Syndr. 1988;2019(80):E14–22.
19.
go back to reference Du Plessis S, Vink M, Joska JA, Koutsilieri E, Stein DJ, Emsley R. HIV infection and the fronto-striatal system: a systematic review and meta-analysis of fMRI studies. AIDS. 2014;28:803–11.CrossRefPubMed Du Plessis S, Vink M, Joska JA, Koutsilieri E, Stein DJ, Emsley R. HIV infection and the fronto-striatal system: a systematic review and meta-analysis of fMRI studies. AIDS. 2014;28:803–11.CrossRefPubMed
20.
go back to reference Hakkers CS, Arends JE, Barth RE, Du Plessis S, Hoepelman AIM, Vink M. Review of functional MRI in HIV: effects of aging and medication. J Neurovirol. 2017;23:20–32.CrossRefPubMed Hakkers CS, Arends JE, Barth RE, Du Plessis S, Hoepelman AIM, Vink M. Review of functional MRI in HIV: effects of aging and medication. J Neurovirol. 2017;23:20–32.CrossRefPubMed
21.
go back to reference Ernst T, Chang L, Jovicich J, Ames N, Arnold S. Abnormal brain activation on functional MRI in cognitively asymptomatic HIV patients. Neurology. 2002;59:1343–9.CrossRefPubMed Ernst T, Chang L, Jovicich J, Ames N, Arnold S. Abnormal brain activation on functional MRI in cognitively asymptomatic HIV patients. Neurology. 2002;59:1343–9.CrossRefPubMed
22.
go back to reference Du Plessis S, Vink M, Joska JA, et al. HIV infection is associated with impaired striatal function during inhibition with normal cortical functioning on functional MRI. J Int Neuropsychol Soc. 2015;21:722–31.CrossRefPubMed Du Plessis S, Vink M, Joska JA, et al. HIV infection is associated with impaired striatal function during inhibition with normal cortical functioning on functional MRI. J Int Neuropsychol Soc. 2015;21:722–31.CrossRefPubMed
23.
go back to reference Tovar-y-Romo LB, Bumpus NN, Pomerantz D, et al. Dendritic spine injury induced by the 8-hydroxy metabolite of efavirenz. J Pharmacol Exp Ther. 2012;343:696–703.CrossRefPubMedPubMedCentral Tovar-y-Romo LB, Bumpus NN, Pomerantz D, et al. Dendritic spine injury induced by the 8-hydroxy metabolite of efavirenz. J Pharmacol Exp Ther. 2012;343:696–703.CrossRefPubMedPubMedCentral
24.
go back to reference Ciavatta VT, Bichler EK, Speigel IA, et al. In vitro and ex vivo neurotoxic effects of efavirenz are greater than those of other common antiretrovirals. Neurochem Res. 2017;42:3220–32.CrossRefPubMed Ciavatta VT, Bichler EK, Speigel IA, et al. In vitro and ex vivo neurotoxic effects of efavirenz are greater than those of other common antiretrovirals. Neurochem Res. 2017;42:3220–32.CrossRefPubMed
25.
go back to reference Toniolo S, Cercignani M, Mora-Peris B, et al. Changes in functional connectivity in people with HIV switching antiretroviral therapy. J Neurovirol. 2020;26:754–63.CrossRefPubMedPubMedCentral Toniolo S, Cercignani M, Mora-Peris B, et al. Changes in functional connectivity in people with HIV switching antiretroviral therapy. J Neurovirol. 2020;26:754–63.CrossRefPubMedPubMedCentral
26.
go back to reference Du Plessis S, Perez A, Fouche JP, et al. Efavirenz is associated with altered fronto-striatal function in HIV+ adolescents. J Neurovirol. 2019;25:783–91.CrossRefPubMed Du Plessis S, Perez A, Fouche JP, et al. Efavirenz is associated with altered fronto-striatal function in HIV+ adolescents. J Neurovirol. 2019;25:783–91.CrossRefPubMed
28.
go back to reference Zandbelt BB, Gladwin TE, Raemaekers M, et al. Within-subject variation in BOLD-fMRI signal changes across repeated measurements: quantification and implications for sample size. Neuroimage. 2008;42:196–206.CrossRefPubMed Zandbelt BB, Gladwin TE, Raemaekers M, et al. Within-subject variation in BOLD-fMRI signal changes across repeated measurements: quantification and implications for sample size. Neuroimage. 2008;42:196–206.CrossRefPubMed
29.
go back to reference Aron AR. From reactive to proactive and selective control: developing a richer model for stopping inappropriate responses. Biol Psychiatry. 2011;69:e55–68.CrossRefPubMed Aron AR. From reactive to proactive and selective control: developing a richer model for stopping inappropriate responses. Biol Psychiatry. 2011;69:e55–68.CrossRefPubMed
30.
go back to reference Ances B, Vaida F, Ellis R, Buxton R. Test-retest stability of calibrated BOLD-fMRI in HIV– and HIV+ subjects. Neuroimage. 2011;54:2156–62.CrossRefPubMed Ances B, Vaida F, Ellis R, Buxton R. Test-retest stability of calibrated BOLD-fMRI in HIV– and HIV+ subjects. Neuroimage. 2011;54:2156–62.CrossRefPubMed
31.
go back to reference Duncan NW, Northoff G. Overview of potential procedural and participant-related confounds for neuroimaging of the resting state. J Psychiatry Neurosci. 2013;38:84–96.CrossRefPubMedPubMedCentral Duncan NW, Northoff G. Overview of potential procedural and participant-related confounds for neuroimaging of the resting state. J Psychiatry Neurosci. 2013;38:84–96.CrossRefPubMedPubMedCentral
32.
go back to reference Yudko E, Lozhkina O, Fouts A. A comprehensive review of the psychometric properties of the drug abuse screening test. J Subst Abuse Treat. 2007;32:189–98.CrossRefPubMed Yudko E, Lozhkina O, Fouts A. A comprehensive review of the psychometric properties of the drug abuse screening test. J Subst Abuse Treat. 2007;32:189–98.CrossRefPubMed
33.
34.
go back to reference Cohen CJ, Molina J-M, Cahn P, et al. Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE trials. J Acquir Immune Defic Syndr. 2012;60:33–42.CrossRefPubMed Cohen CJ, Molina J-M, Cahn P, et al. Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE trials. J Acquir Immune Defic Syndr. 2012;60:33–42.CrossRefPubMed
35.
go back to reference Wechsler D. Wechsler adult intelligence scale - Nederlandstalige bewerking 1E. Amsterdam: Pearson; 2013. Wechsler D. Wechsler adult intelligence scale - Nederlandstalige bewerking 1E. Amsterdam: Pearson; 2013.
36.
go back to reference Reitan R, Wolfson D. The halstead-reitan neuropsychological test battery: therapy and clinical interpretation. 1st edn. Indiana: Neuropsychology Press; 1985. Reitan R, Wolfson D. The halstead-reitan neuropsychological test battery: therapy and clinical interpretation. 1st edn. Indiana: Neuropsychology Press; 1985.
37.
go back to reference Gronwall D, Sampson H. The psychological effects of concussion. 1st edn. Michigan: Auckland University Press; 1974. Gronwall D, Sampson H. The psychological effects of concussion. 1st edn. Michigan: Auckland University Press; 1974.
38.
go back to reference Logan GD, Cowan WB. On the ability to inhibit thought and action: a theory of an act of control. Psychol Rev. 1984;91:295–327.CrossRef Logan GD, Cowan WB. On the ability to inhibit thought and action: a theory of an act of control. Psychol Rev. 1984;91:295–327.CrossRef
39.
go back to reference van Dijk KRA, Sabuncu MR, Buckner RL. The influence of head motion on intrinsic functional connectivity MRI. Neuroimage. 2012;59:431–8.CrossRefPubMed van Dijk KRA, Sabuncu MR, Buckner RL. The influence of head motion on intrinsic functional connectivity MRI. Neuroimage. 2012;59:431–8.CrossRefPubMed
40.
go back to reference Chang L, Speck O, Miller EN, et al. Neural correlates of attention and working memory deficits in HIV patients. Neurology. 2001;57:1001–7.CrossRefPubMed Chang L, Speck O, Miller EN, et al. Neural correlates of attention and working memory deficits in HIV patients. Neurology. 2001;57:1001–7.CrossRefPubMed
41.
go back to reference Chang L, Yakupov R, Nakama H, Stokes B, Ernst T. Antiretroviral treatment is associated with increased attentional load-dependent brain activation in HIV patients. J Neuroimmune Pharmacol. 2008;3:95–104.CrossRefPubMed Chang L, Yakupov R, Nakama H, Stokes B, Ernst T. Antiretroviral treatment is associated with increased attentional load-dependent brain activation in HIV patients. J Neuroimmune Pharmacol. 2008;3:95–104.CrossRefPubMed
42.
go back to reference Baldewicz TT, Leserman J, Silva SG, et al. Changes in neuropsychological functioning with progression of HIV-1 infection: results of an 8-year longitudinal investigation. AIDS Behav. 2004;8:345–55.CrossRefPubMed Baldewicz TT, Leserman J, Silva SG, et al. Changes in neuropsychological functioning with progression of HIV-1 infection: results of an 8-year longitudinal investigation. AIDS Behav. 2004;8:345–55.CrossRefPubMed
43.
go back to reference du Plessis S, Vink M, Joska JA, et al. HIV infection results in ventral-striatal reward system hypo-activation during cue processing. AIDS. 2015;29:1335–43.CrossRefPubMed du Plessis S, Vink M, Joska JA, et al. HIV infection results in ventral-striatal reward system hypo-activation during cue processing. AIDS. 2015;29:1335–43.CrossRefPubMed
Metadata
Title
Underlying Neural Mechanisms of Cognitive Improvement in Fronto-striatal Response Inhibition in People Living with HIV Switching Off Efavirenz: A Randomized Controlled BOLD fMRI Trial
Authors
Patrick G. A. Oomen
Charlotte S. Hakkers
Joop E. Arends
Guido E. L. van der Berk
Pascal Pas
Andy I. M. Hoepelman
Berend J. van Welzen
Stefan du Plessis
Publication date
20-04-2024
Publisher
Springer Healthcare
Published in
Infectious Diseases and Therapy
Print ISSN: 2193-8229
Electronic ISSN: 2193-6382
DOI
https://doi.org/10.1007/s40121-024-00966-7
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.